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Abstract
Background: Breast cancer is one of the most frequently diagnosed cancer and accounts for over 400,000 deaths each 
year worldwide. It causes premature death in women, despite progress in early detection, treatment, and advances in 
understanding the molecular basis of the disease. Therefore, it is important to understand the in depth mechanism of 
tumor progression and develop new strategies for the treatment of breast cancer. Thus, this study is aimed at gaining 
an insight into the molecular mechanism by which osteopontin (OPN), a member of SIBLING (Small Integrin Binding 
LIgand N-linked Glycoprotein) family of protein regulates tumor progression through activation of various transcription 
factors and expression of their downstream effector gene(s) in breast cancer.
Results: In this study, we report that purified native OPN induces ICAM-1 expression in breast cancer cells. The data 
revealed that OPN induces NF-κB activation and NF-κB dependent ICAM-1 expression. We also observed that OPN-
induced NF-κB further controls AP-1 transactivation, suggesting that there is cross talk between NF-κB and AP-1 which 
is unidirectional towards AP-1 that in turn regulates ICAM-1 expression in these cells. We also delineated the role of 
mTOR and p70S6 kinase in OPN-induced ICAM-1 expression. The study suggests that inhibition of mTOR by rapamycin 
augments whereas overexpression of mTOR/p70S6 kinase inhibits OPN-induced ICAM-1 expression. Moreover, 
overexpression of mTOR inhibits OPN-induced NF-κB and AP-1-DNA binding and transcriptional activity. However, 
rapamycin further enhanced these OPN-induced effects. We also report that OPN induces p70S6 kinase 
phosphorylation at Thr-421/Ser-424, but not at Thr-389 or Ser-371 and mTOR phosphorylation at Ser-2448. 
Overexpression of mTOR has no effect in regulation of OPN-induced phosphorylation of p70S6 kinase at Thr-421/Ser-
424. Inhibition of mTOR by rapamycin attenuates Ser-371 phosphorylation but does not have any effect on Thr-389 and 
Thr-421/Ser-424 phosphorylation of p70S6 kinase. However, OPN-induced phosphorylation of p70S6 kinase at Thr-
421/Ser-424 is being controlled by MEK/ERK pathway.
Conclusion: These results suggest that blocking of OPN-induced ICAM-1 expression through mTOR/p70S6 kinase 
signaling pathway may be an important therapeutic strategy for the treatment of breast cancer.
Introduction
Breast cancer is one of the major causes of death among
all other cancers in women globally. It emerges through a
multi-step process starting from hyperplasia to premalig-
nant change, in situ carcinoma, and invasive breast can-
cer [1-3]. Osteopontin (OPN), a calcified ECM associated
non collagenous, sialic acid rich, glycosylated phosphop-
rotein is secreted by majority of the normal and trans-
formed cells [4]. OPN isolated from different cellular
sources, have molecular weight ranging from 44 kDa to
75 kDa due to differences in the post translational modifi-
cations [4]. Many highly metastatic transformed cells
synthesize high level of OPN than their normal counter
parts. Recently it has been reported that OPN plays cru-
cial role in cell migration and invasion by interacting with
its receptor αvβ3 integrin by inducing the expression of
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urokinase plasminogen activator (uPA) and activation of
matrix metalloproteinases (MMPs) in various cancer cells
[5-9]. Increased level of OPN has been reported in num-
ber of human carcinomas, glioblastoma, and osteosar-
coma and considered as a lead marker during breast
cancer progression [10].
The mammalian target of rapamycin (mTOR), (also
known as FRAP/RAFT/RAPT), a member of the phos-
phatidylinositol 3-kinase-related kinase (PIKK) super
family, is consisted of 2549 amino acids that are grouped
into highly conserved domains [11,12]. Previous reports
have indicated that mTOR acts as a downstream mole-
cule in the PI 3-kinase/Akt signaling pathway. It is an evo-
lutionarily conserved 289-kDa serine-threonine kinase
that regulates both cell growth and cell-cycle progression
through its ability to integrate signals in response to
nutrients and growth factors. mTOR is phosphorylated at
Ser-2448 via the PI 3-kinase/Akt pathway and autophos-
phorylates at Ser-2481 [12-14]. mTOR initiates transla-
tion by activating the p70S6 kinase (S6K1) and by
inhibiting the eIF4E inhibitor, 4E-BP1. By targeting
mTOR, the immunosuppressant and anti-proliferative
agent, rapamycin inhibits the signals required for cell-
cycle progression, cell growth and proliferation in both
normal and malignant cells. Interaction of FKBP12
(immunophilin FK506 binding protein 12 kDa)-rapamy-
cin complex with mTOR inhibits its function and leads to
dephosphorylation and inactivation of p70S6 kinase [14-
16]. As a result, mTOR may act as an important target for
regulation of cancer progression. Activation of p70S6
kinase involves a complex interplay among sequential
phosphorylation events, which occur within distinct
intramolecular regulatory domains. Phosphorylation of
p70S6 kinase at Thr-421/Ser-424 exists in the autoinhibi-
tory domain of carboxyl terminal, Thr-229 in activation
loop, Thr-389 and Ser-371 in the linker domain, are very
important for the activation of p70S6 kinase [17,18]. The
phosphorylation of p70S6 kinase at Thr-421/Ser-424
leads the phosphorylation of other regulatory site by
release of pseudosubstrate suppression in the autoinhibi-
tory domain leading to modulation of the kinase activity
[19,20]. However, the mechanism by which OPN regu-
lates mTOR/p70S6 kinase activation in breast cancer cells
is not well defined.
Nuclear factor κB (NF-κB) and activator protein-1 (AP-
1) are key transcription factors that regulate the expres-
sion of many genes involved in inflammation, apoptosis,
and oncogenesis [21]. Many reports have demonstrated
that these transcription factors are thought to be regu-
lated by the same intracellular signal transduction path-
way. The activity of NF-κB is regulated by its interaction
with the family of NF-κB inhibitor known as IκB, which
results in the formation of inactive NF-κB-IκB complex in
the cytoplasm. In response to various stimuli, IκB kinase
(IKK) phosphorylates IκB. The subsequent proteosome
mediated degradation of IκB expose the nuclear localiza-
tion signal of NF-κB, thus allowing its translocation to the
nucleus where it activates the transcription of various tar-
get genes including ICAM-1 [21-23]. AP-1 is a group of
basic leucine zipper (bZIP) transcription factor consist-
ing of the Fos and Jun families. Extracellular stimuli and
growth factor stimulate MAPK pathways which play
important role in regulation of transcription factor AP-1,
as its activation leads to the induction of c-Fos which
associate to c-Jun to form an AP-1 heteromeric complex
that can promote target gene expression [21,24]. Our pre-
vious results showed that OPN induces cell motility,
tumor growth and angiogenesis through NF-κB and AP-1
dependent activation and expressions of MMP-2, -9, uPA,
Cox-2 and VEGF in various cancer cells [10,25]. However,
the signaling pathways by which OPN controls NF-κB
and AP-1 activation and whether there is any cross talk
between NF-κB and AP-1 in regulation of ICAM-1
expression is not well understood.
Cell adhesion is a crucial step for normal development
and maintenance of tissues and organs. Cell-cell and cell-
matrix interaction are mediated by dynamic interaction
between various cell surface receptors which play impor-
tant role in regulation of cancer progression. Based on
the structure and functions, adhesion molecules are clas-
sified into four major categories: integrins, cadherins,
selectins and immunoglobulins superfamilies. The vari-
ous cell adhesion molecules also function as receptors for
various ligands thereby control signal transduction path-
ways which ultimately regulate cell adhesion, prolifera-
tion, migration and differentiation [26,27]. Intercellular
adhesion molecule-1 (ICAM-1), also known as CD54 is a
cell surface glycoprotein that belongs to the immuno-
globin superfamily of adhesion molecules. It is expressed
in br eas t ca nc e r t iss ues. T he  pr oc ess  of  t um or  gr owt h
involves alterations in expression of adhesion molecules
that may lead to destruction of tissue architecture leading
to metastasis [28-30]. The mechanisms by which OPN
regulates ICAM-1 expression through mTOR/p70S6
kinase and NF-κB/AP-1 pathways are not defined well.
I n  s u m m a r y ,  w e  r e p o r t  t h a t  O P N  r e g u l a t e s  N F - κ B
mediated ICAM-1 expression in breast cancer cells.
OPN-induced NF-κB controls unidirectional AP-1 acti-
vation, indicating a cross talk between NF-κB and AP-1
which in turn regulates ICAM-1 expression in these cells.
We also investigated the role of mTOR and p70S6 kinase
in OPN-induced ICAM-1 expression. Our results
revealed that both mTOR and p70S6 kinase are involved
in OPN-induced ICAM-1 expression. Overexpression of
mTOR inhibits OPN-induced NF-κB and AP-1 DNA-
binding and transcriptional activity. OPN selectively
induces p70S6 kinase phosphorylation at Thr-421/Ser-
424. However, overexpression of mTOR has no effect onAhmed and Kundu Molecular Cancer 2010, 9:101
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regulation of OPN-induced Thr-421/Ser-424 phosphory-
lation. Inhibition of mTOR by rapamycin attenuates Ser-
371 phosphorylation of p70S6 kinase. Moreover, OPN-
induced phosphorylation of p70S6 kinase at Thr-421/Ser-
424 is being controlled by MEK/ERK pathway. Thus,
blocking OPN-induced ICAM-1 expression through
mTOR and p70S6 kinase pathway may act as important
target for the control of breast cancer.
Materials and methods
Antibodies, Reagents, and Cell Lines
Rabbit polyclonal anti-ICAM-1, goat polyclonal anti-
actin, mouse monoclonal anti-p70S6 kinase, mouse anti-
p-ERK1/2 and rabbit anti-ERK2 antibodies were pur-
chased from Santa Cruz Biotechnology. Rabbit anti-p-
mTOR antibody was purchased from R&D Systems. Rab-
bit anti-mTOR, anti-p-p70S6K antibodies and rapamycin
were purchased from Cell Signaling Technology. U0126
was obtained from Calbiochem. Anti-human αvβ3 integ-
rin (MAB1976) blocking antibody was from Chemicon
International. Lipofectamine 2000 was purchased from
Invitrogen. AP-1 consensus oligonucleotide was pur-
chased from Santa Cruz and NF-κB consensus oligonu-
cleotide was purchased from Promega. The [γ-32p] ATP
was purchased from Board of Radiation and Isotope
Technology (Hyderabad, India). The human OPN was
purified from milk as described previously [7] with minor
modifications and used throughout this study. The low
invasive (MCF-7) and highly invasive (MDA-MB-468)
breast cancer cells were purchased from American Type
Culture Collection (Manassas, VA). These cells were cul-
tured in Dulbecco's modified Eagle's medium (DMEM)
and leibovitz's L-15 supplemented with 10% fetal calf
serum, 100 units/ml penicillin, 100 μg/ml streptomycin
and 2 mM glutamine in a humidified atmosphere at 37°C.
Plasmids and DNA Transfection
The wild type and rapamycin resistant mTOR in pIRES-
GFP expression vector were a generous gift from Dr. Rok
Humar (University Hospital Basel, Switzerland). The wild
type and rapamycin resistant HA-S6K1 (p70S6 kinase 1)
in pRK7 expression vector were kind gift from Dr. John
Blenis (Harvard Medical School, Boston). The super-
r e p r e s s o r  f o r m  o f  I κ B α  f u s e d  d o w n s t r e a m  t o  a  F LA G
epitope in an expression vector (pCMV4) was a gift from
Dr. Dean Ballard (Vanderbilt School of Medicine, Nash-
ville, TN). The wild type pCEFL-GFP-c-Fos was a kind
gift from Dr. Omar A Coso (Laboratorio de Fisiologia y
Biologia Molecular. Facultad de Ciencias Exactas y Natu-
rales. Universidad de Buenos Aires. IFIBYNE-CONICET.
ARGENTINA). The dominant negative c-Fos (also called
as A-Fos) in pCMV500 expression vector was a kind gift
from Dr. Nicole Darack (NCI, NIH). The wild type c-Jun
in pRJB10B expression vector and dominant negative c-
Jun in pELFIN expression vector were kind gifts from Dr.
Jalam (Ochsner Clinic foundation, New Orleans, LA).
The ICAM-1 Luc (containing 1393 bp of ICAM-1 pro-
moter) construct was a kind gift from Dr. Arshad Rahman
(University of Rochester School of Medicine, Rochester,
New York). The MCF-7 cells were transiently transfected
with cDNA using Lipofectamine 2000 according to man-
ufacturer's instructions (Invitrogen). Transfected cells
were used for ICAM-1 expression, NF-κB and AP-1-
DNA binding, NF-κB, AP-1 and ICAM-1 luciferase
assays and p70S6 kinase phosphorylation studies.
Western Blot Analysis
For ICAM-1 expression, MCF-7 and MDA-MB-468 cells
were treated with OPN in a time and dose dependent
manner. In separate experiments, MCF-7 cells were
either transfected with various cDNA constructs or pre-
treated with 20 nM rapamycin for 1 h and then treated
with 0.5 μM OPN and level of ICAM-1 was detected. For
p70S6 kinase and mTOR phosphorylations, cells were
treated with 0.5 μM OPN for 0-120 min. In other experi-
ments, the cells were either transfected with mTOR con-
structs or pretreated with 20 nM rapamycin or 0-500 μM
U0126 for 1 h and then treated with 0.5 μM OPN. The
cells were lysed in lysis buffer (50 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxy-
cholate, 5 mM dithiothreitol and 1 mM phenylmethylsul-
fonyl fluoride) and the protein concentrations in cleared
supernatants were measured by using Bio-Rad protein
assay. The supernatant (lysates) containing equal amount
of total proteins (30 μg) were resolved by SDS-PAGE and
electrotransferred from gel to nitrocellulose membranes.
The membranes were incubated with anti-p-p70S6K,
anti-p-mTOR, anti-p-ERK1/2 or anti-ICAM-1 antibodies
and further incubated with horseradish peroxidase-con-
jugated IgG and detected by luminol reagent (Santa Cruz)
according to the manufacturer's instruction. The same
blots were re-probed with anti-actin or non phospho
antibodies of respective molecules and detected.
Nuclear Extracts and Electrophoretic Mobility Shift Assay 
(EMSA)
The NF-κB and AP-1 EMSA were performed as
described earlier [8]. Briefly, MCF-7 cells were treated
with 0.5 μM OPN for 0-240 min at 37°C. In another
experiments, cells were transfected with mTOR, treated
with 20 nM rapamycin for 1 h and then with 0.5 μM OPN
for 30 min. In separate experiments, cells were trans-
fected with wt c-Jun, dominant negative c-Jun, c-Fos and
A-Fos cDNAs and then treated with 0.5 μM OPN for 30
min. Cells were scraped, washed with phosphate-buffered
saline (pH 7.4) and resuspended in hypotonic buffer (10
mM Hepes, (pH 7.9), 1.5 mM MgCl2, 10 mM KCl, 0.2
mM phenylmethylsulfonyl fluoride, and 0.5 mM dithio-Ahmed and Kundu Molecular Cancer 2010, 9:101
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threitol), and allowed to swell on ice for 10 min. Cells
were homogenized in a Dounce homogenizer. The nuclei
were separated by spinning at 3300 ×g for 15 min at 4°C.
The nuclear pellet was extracted in nuclear extraction
buffer (20 mM Hepes, (pH 7.9), 0.4 M NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 2.5% glycerol, 0.5 mM phenylm-
ethylsulfonyl fluoride and 0.5 mM DTT) for 30 min on
ice, and centrifuged at 12,000 ×g for 15 min at 4°C. The
supernatant was used as nuclear extract. The protein
concentrations in the supernatant of nuclear extracts
were measured by Bio-Rad protein assay. The nuclear
extracts (10 μg) were incubated with 16 fmol of 32P
labeled double stranded NF-κB (5'-AGT TGA GGG GAC
TTT CCC AGG C-3') and AP-1 (5'-CGC TTG ATG ACT
CAG CCG GAA-3') consensus oligonucleotide in binding
buffer (250 mM Hepes, (pH 7.9), 5 mM EDTA, 5 mM
DTT, 10% Nonidet P-40, 50% glycerol, and 500 mM
NaCl) containing 1 μg of salmon sperm DNA. The DNA-
protein complex was resolved on a native polyacrylamide
gel, and analyzed by autoradiography.
Luciferase Reporter Gene Assay
The luciferase reporter gene assay was done as described
[6]. Briefly, MCF-7 cells were transfected with ICAM-1-
Luc using Lipofectamine 2000 and treated with 20 nM
rapamycin for 1 h and then with 0.5 μM OPN. In separate
experiments, MCF-7 cells were transfected with NF-κB-
Luc or AP-1-Luc and then either cotransfected with wt
mTOR, rapamycin resistance mTOR or pretreated with
20 nM rapamycin for 1 h and then treated with OPN. In
other experiments, cells were transfected with AP-1-Luc
and cotransfected with IκBα super repressor or treated
with 10 μg/ml anti-αvβ3 integrin blocking antibody for 3 h
and then treated with OPN. In another experiments, cells
were transfected with NF-κB-Luc and then either
cotransfected with wt and dominant negative c-Jun, c-Fos
or A-Fos and then treated with OPN. The transfection
efficiency was normalized by cotransfecting the cells with
pRL vector (Promega) containing a full length Renilla
luciferase gene under the control of constitutively active
promoter. The cells were harvested in passive lysis buffer
and the luciferase activity was measured using the dual
luciferase assay system (Promega) according to the manu-
facturer instruction. Changes in activity with respect to
control were calculated.
Results
OPN-induces ICAM-1 expression in breast cancer cells
To determine whether OPN-induces ICAM-1 expression,
MCF-7 or MDA-MB-468 cells were treated with 0.5 μM
OPN for 0-24 h and the expression of ICAM-1 in cell
lysates were detected by western blot. The data indicated
that OPN induces ICAM-1 expression in time dependent
manner in these cells (Fig. 1A &1C, upper panels). The
dose dependent response of OPN (0-5.0 μM) on ICAM-1
expression was also detected in these cells and the results
showed that the expression of ICAM-1 increases in dose
dependent manner and 0.5 μM OPN exhibit significantly
high level of ICAM-1 expression as compared to
untreated cells (Fig. 1B &1D, upper panels). Actin was
used as loading control (Fig. 1A-D, lower panels).
Both mTOR and p70S6 kinase suppress OPN-induced NF-κB 
and AP-1 mediated ICAM-1 expression
To examine the role of mTOR signaling in OPN-induced
ICAM-1 expression; MCF-7 cells were individually trans-
fected with wild type or rapamycin resistant m T OR or
pretreated with rapamycin and then treated with OPN.
Cell lysates were analyzed by western blot using anti-
ICAM-1 antibody. The results indicated that overexpres-
sion of wt or rapamycin resistant mTOR inhibits whereas
rapamycin enhances OPN-induced ICAM-1 expression
suggesting that mTOR is involved in this process (Fig.
2A). To investigate the role of p70S6 kinase in OPN-
induced ICAM-1 expression, cells were transfected with
Figure 1 OPN-induces ICAM-1 expression in breast cancer cells. A 
and C. MCF-7 or MDA-MB-468 cells were treated with 0.5 μM OPN in 
serum free medium for 0-24 h. B and D. In a separate experiments, 
MCF-7 or MDA-MB-468 cells were treated with various concentrations 
of OPN (0-5.0 μM) for 24 h. Cell lysates containing equal amount of total 
proteins were analyzed by western blot using anti-ICAM-1 antibody. 
Actin was used as loading control.Ahmed and Kundu Molecular Cancer 2010, 9:101
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wild type or rapamycin resistant p70S6 kinase or pre-
treated with rapamycin and then treated with OPN. The
cell lysates were analyzed by western blot using anti-
ICAM-1 antibody and the data shown that overexpres-
sion of wt or rapamycin resistant p70S6 kinase attenuates
whereas rapamycin augments OPN-induced ICAM-1
expression indicating that p70S6 kinase plays important
role in this process (Fig. 2B).
To further study the role of mTOR/p70S6 kinase on
ICAM-1 transcriptional activity in response to OPN; cells
were transiently transfected with ICAM-1 luciferase
reporter construct. Transfected cells were treated with
rapamycin and then with OPN. The transfection effi-
ciency was normalized by cotransfecting the cells with
Renilla luciferase vector. Changes in luciferase activity
with respect to control were calculated. The results indi-
cated that OPN induces ICAM-1 transcriptional activity
and rapamycin augments ICAM-1 transcription in
response to OPN (Fig. 2C). To assess the role of NF-κB
and AP-1 in OPN-induced ICAM-1 expression, MCF-7
cells were individually transfected with IκBα super
repressor, wt and dominant negative c-Jun, and A-Fos
and then treated with OPN. Cell lysates were analyzed by
western blot using anti-ICAM-1 antibody. The results
indicated that IκBα super repressor, dominant negative c-
Jun and A-Fos suppressed whereas wt c-Jun enhanced
OPN-induced ICAM-1 expression (Fig. 2D). Actin was
used as loading control.
mTOR plays crucial role in OPN-induced NF-κB activation
To investigate the effect of OPN on NF-κB-DNA binding
in a time dependent manner, MCF-7 cells were treated
with OPN for 0-240 min; nuclear extracts were prepared
and analyzed by EMSA. The data showed that OPN
induces NF-κB-DNA binding in a time dependent man-
ner, with maximum binding at 30 min (Fig. 3A). To exam-
ine the role of mTOR on OPN-induced NF-κB-DNA
binding; cells were either transiently transfected with wt
type mTOR or rapamycin resistant mTOR, treated with
rapamycin and then with OPN. The data suggested that
mTOR inhibits OPN-induced NF-κB-DNA binding (Fig.
3B). To elucidate the role of mTOR on OPN-induced NF-
Figure 2 Both mTOR and p70S6 kinase suppress OPN-induced NF-κB and AP-1 mediated ICAM-1 expression. A. MCF-7 cells were transfected 
with wild type or rapamycin resistant mTOR or pretreated with 20 nM rapamycin for 1 h and then treated with 0.5 μM OPN for 24 h. B. In another 
experiments, MCF-7 cells were transfected with wild type or rapamycin resistant p70S6 kinase or pretreated with 20 nM rapamycin and then treated 
with OPN under the same condition as mentioned above. Cell lysates were analyzed by western blot using anti-ICAM-1 antibody. Actin was used as 
loading control. C.MCF-7 cells were transfected with ICAM-1 luciferase reporter construct along with Renilla luciferase and then treated with 0.5 μM 
OPN for 24 h or pretreated with rapamycin (20 nM) for 1 h and then treated with OPN. The transfection efficiency was normalized and fold changes 
in luciferase activity with respect to control were calculated, and mean ± S.D. of triplicate determinations are plotted. The values were also analyzed 
by One Way ANOVA (*, p > 0.05; **, p > 0.05). D. MCF-7 cells were individually transfected with IκBα sup. rep., wild type and dominant negative c-Jun 
or A-Fos and then treated with 0.5 μM OPN for 24 h. Cell lysates were analyzed by western blot using anti-ICAM-1 antibody. Actin was used as loading 
control.Ahmed and Kundu Molecular Cancer 2010, 9:101
http://www.molecular-cancer.com/content/9/1/101
Page 6 of 13
κB transcriptional activity; cells were either transiently
transfected with wt type mTOR or rapamycin resistant
m T O R  a l o n g  w i t h  N F - κ B  l u c i f e r a s e  r e p o r t e r  c o n s t r u c t
(pNF-κB-Luc) or pretreated with rapamycin and then
with OPN. Changes in luciferase activity with respect to
control were calculated. The transfection efficiency was
normalized by transfecting the cells with Renilla
luciferase vector. The results indicated that the level of
OPN-induced NF-κB transcriptional activity in mTOR
transfected cells decreased as compared to cells treated
with OPN alone or rapamycin along with OPN. The data
suggested that overexpression of mTOR inhibits OPN-
induced NF-κB transactivation (Fig. 3C).
OPN-induced AP-1 activation is downregulated by mTOR
To check the effect of OPN on AP-1-DNA binding, MCF-
7 cells were treated with OPN for 0-240 min; nuclear
extracts were prepared and analyzed by EMSA. The data
showed that OPN induces AP-1-DNA binding maximum
at 30 min (Fig. 4A). To further examine the role of mTOR
on AP-1-DNA binding; cells were either transiently trans-
fected with wt m TOR or rapamycin resistant m TOR in
absence or presence of rapamycin and then treated with
OPN. The data suggested that mTOR inhibits OPN-
induced AP-1-DNA binding (Fig. 4B). To elucidate the
role of mTOR on OPN-induced AP-1 transcriptional
activity; cells were either transiently transfected with wt
m T O R  a l o n g  w i t h  A P - 1  l u c i f e r a s e  r e p o r t e r  c o n s t r u c t
(pAP-1-Luc) and then treated in absence or presence of
OPN. In separate experiments, rapamycin resistant
mTOR transfected cells were pretreated with rapamycin
and then treated with or without OPN and changes in
luciferase activity with respect to control were calculated.
The transfection efficiency was normalized by transfect-
Figure 3 mTOR suppresses OPN-induced NF-κB Activation. A and B. MCF-7 cells were treated with 0.5 μM OPN for 0-240 min or transiently trans-
fected with wild type or rapamycin resistant mTOR and then treated with OPN. The non-transfected or transfected cells were treated with rapamycin 
alone or along with OPN under the same condition as described in Materials and Methods. Nuclear extracts were prepared and analyzed by EMSA. C. 
MCF-7 cells were transfected with wt or rapamycin resistant mTOR along with NF-κB luciferase reporter construct and then treated with 0.5 μM OPN. 
The non-transfected or transfected cells were treated with rapamycin alone or along with OPN. The transfection efficiency was normalized by Renilla 
and fold changes in luciferase activity with respect to control were calculated, and mean ± S.D. of triplicate determinations are plotted. The values 
were also analyzed by One Way ANOVA (*, p < 0.05; **, p < 0.05).Ahmed and Kundu Molecular Cancer 2010, 9:101
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ing the cells with Renilla luciferase vector. The results
indicated that the level of AP-1 transcriptional activity in
mTOR transfected cells decreased as compared to cells
treated with OPN alone or rapamycin along with OPN
(Fig. 4C). The data reveals that overexpression of mTOR
inhibits OPN-induced AP-1 transactivation.
OPN-induced cross talk between NF-κB and AP-1 is 
unidirectional towards AP-1
To investigate the involvement of αvβ3 integrin and NF-κB
in OPN-induced AP-1 transcriptional activity, cells were
transiently transfected with IκBα super repressor (IκBα
sup. rep.) along with AP-1 luciferase reporter construct
(pAP-1 Luc) and then treated with OPN. In separate
experiments, AP-1-Luc transfected cells were pretreated
with αvβ3 integrin blocking antibody and then treated
with OPN. The transfection efficiency was normalized by
transfecting the cells with pRL vector and changes in
luciferase activity with respect to control were calculated.
The data indicates that αvβ3 integrin blocking antibody or
IκBα sup. rep. suppresses OPN-induced AP-1 transcrip-
tional activity (Fig. 5A). To examine whether AP-1 is also
involved in regulation of OPN induced NF-κB activation,
cells were individually transfected with wt and dominant
negative c-Jun, c-Fos or A-Fos and then treated with OPN
and EMSA was performed. The results indicated that wt
and dominant negative c-Jun, c-Fos and A-Fos had no
effect on OPN-induced NF-κB-DNA binding (Fig. 5B).
This was further confirmed by NF-κB luciferase assay
(Fig. 5C) under the same conditions as described in Fig.
5B. The results revealed that AP-1 or its components
have no effect on OPN-induced NF-κB activation (Fig. 5B
and 5C) and further confirmed that OPN-induced NF-κB
regulates AP-1 activation in a unidirectional manner.
Figure 4 mTOR down reguates OPN-induced AP-1 activation. A and B. MCF-7 cells were treated with 0.5 μM OPN for 0-240 min or transiently 
transfected with wild type or rapamycin resistant mTOR and then treated with OPN. The non-transfected or transfected cells were treated with ra-
pamycin alone or along with OPN. Nuclear extracts were prepared and analyzed by EMSA. C. MCF-7 cells were transiently transfected with wild type 
or rapamycin resistant mTOR along with pAP-1-Luc. The non-transfected or transfected cells were treated with rapamycin alone or along with OPN. 
The transfection efficiency was normalized by Renilla and fold changes in luciferase activity with respect to control were calculated, and mean ± S.D. 
of triplicate determinations are plotted. The values were also analyzed by One Way ANOVA (*, p < 0.05; **, p < 0.05).Ahmed and Kundu Molecular Cancer 2010, 9:101
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OPN induces phosphorylation of p70S6 kinase at Thr-421/
Ser-424, but not at Thr-389 and Ser-371 and has no effect 
on mTOR phosphorylation at Ser-2448
To study the effect of OPN on phophorylation of mTOR
and p70S6 kinase, MCF-7 cells were either treated with
OPN for 0-120 min or pretreated with 20 nM rapamycin
for 1 h and then treated with OPN for 10 min. The results
indicated that OPN has no effect on mTOR phosphoryla-
tion at Ser-2448 and p70S6 kinase phosphorylation at
Thr-389 and Ser-371, while it does induce p70S6 kinase
phosphorylation at Thr-421/Ser-424. Rapamycin sup-
presses basal level phosphorylation of p70S6 kinase at
Ser-371 but does not have any effect on Thr-389 and Thr-
421/Ser-424 phosphorylation (Fig. 6, panels A-D).
OPN induces mTOR independent p70S6 kinase 
phosphorylation at Thr-421/Ser-424 through MEK/ERK 
pathway
To delineate the role of mTOR on p70S6 kinase phospho-
rylation at Thr-421/Ser-424, MCF-7 cells were either
transiently transfected with wt or rapamycin resistant
mTOR or pretreated with rapamycin (20 nM) for 1 h and
then treated with OPN for 10 min. The results revealed
that mTOR does not play any role in OPN-induced p70S6
Figure 5 NF-κB regulates OPN-induced AP-1 activation. A. MCF-7 cells were transfected with pAP-1-Luc along with Renilla luciferase and then 
either treated with OPN alone or pretreated with anti-αvβ3 integrin blocking antibody along with OPN. In separate experiments, cells were transfected 
with IκBα super-repressor along with pAP-1-Luc and then treated with OPN. The transfection efficiency was normalized by Renilla and fold changes 
in luciferase activity with respect to control were calculated, and mean ± S.D. of triplicate determinations are plotted. The values were also analyzed 
by One Way ANOVA (*, p < 0.05; **, p < 0.05). B. MCF-7 cells were individually transfected with wild type and dominant negative c-Jun, wild type c-
Fos, A-Fos and then treated with OPN for 30 min. Nuclear extracts were prepared and analyzed by EMSA. C. MCF-7 cells were individually transfected 
with wild type and dominant negative c-Jun, wild type c-Fos, A-Fos along with pNF-κB-Luc and then treated with OPN for 24 h. The transfection effi-
ciency was normalized by Renilla and fold changes in luciferase activity with respect to control were calculated, and mean ± S.D. of triplicate deter-
minations are plotted. The values were also analyzed by One Way ANOVA (*, p < 0.05; **, p < 0.05).Ahmed and Kundu Molecular Cancer 2010, 9:101
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kinase phosphorylation at Thr-421/Ser-424 (Fig. 7A). To
examine the role of MEK/ERK on p70S6 kinase phospho-
rylation at Thr-421/Ser-424, cells were pretreated with
MEK inhibitor, U0126, for 1 h and then treated with OPN
for 10 min. The results indicated that U0126 inhibits
OPN-induced p70S6 kinase phosphorylation at Thr-421/
Ser-424 (Fig. 7B) suggesting that MEK/ERK pathway
plays significant role in p70S6 kinase phosphorylation in
response to OPN.
Discussion
Recent reports demonstrated that both stroma and tumor
derived OPN regulate breast tumor progression. OPN is a
matrix associated ECM protein and it's over expression
confers malignant transformation in a variety of tumori-
genic cell lines [10]. OPN was found to be a metastasis
associated protein in breast cancer. Rudland et al have
r e p o r t e d  t h a t  m a j o r i t y  o f  t h e  b r e a s t  c a n c e r  p a t i e n t s
showed significantly higher level of OPN expression than
normal individuals [31]. The level of serum OPN in
patients with breast, lung and prostate cancers is higher
as compared to controls. The concentration of OPN
required in controlling various cellular signaling events
leading to tumor progression is varied significantly. Ear-
lier reports have shown that nanomolar concentrations of
OPN regulate cell adhesion and migration through PI 3-
kinase-dependent Akt phosphorylation pathway in pros-
tate cancer cells. However, other studies have indicated
that micromolar concentrations of OPN are required to
regulate tumor growth through PI 3-kinase dependent
uPA secretion and MMP activation in various cancer
cells. Therefore, different concentrations of OPN might
regulate these cellular functions depending on the degree
of posttranslational modification, the sources from which
it is obtained and the nature of cell lines used [10,32].
Thus the role of OPN in various pathophysiological con-
ditions, particularly in cancer, suggested that the varia-
tion in post-translational modification such as
glycosylation, phosphorylation and sulfation generate the
different functional forms that might alter its normal
physiological functions.
Recently, Rosette et al. have reported that ICAM-1 is
likely to play a major role in invasion of cancer cells lead-
ing to tumor growth and metastasis in breast cancer [29].
Figure 6 OPN induces phosphorylation of p70S6 kinase at Thr-421/Ser-424, but not at Thr-389 and Ser-371 and has no effect on mTOR 
phosphorylation. A-D. MCF-7 cells were either treated with 0.5 μM OPN for 0-120 min or pretreated with 20 nM rapamycin for 1 h and then treated 
with 0.5 μM OPN for 10 min. Cell lysates containing equal amount of total proteins were resolved by SDS-PAGE and immunoblotted with anti-p-mTOR 
or anti-p-p70S6 kinase (Thr-421/Ser-424, Ser-371 or Thr-389) antibody. These blots were reprobed with anti-mTOR or anti-p70S6 kinase antibody.Ahmed and Kundu Molecular Cancer 2010, 9:101
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However, the mechanism by which OPN regulates
ICAM-1 expression in breast cancer cells is not well
defined. Here, we provide the experimental evidence
indicating that OPN induces ICAM-1 expression in
breast cancer, MCF-7 cells. We also examined the role of
mTOR and its downstream molecule, p70S6 kinase, in
OPN-induced ICAM-1 expression and the data suggest
t h a t  o v e r e x p r e s s i o n  o f  b o t h  m T O R  a n d  p 7 0 S 6  k i n a s e
inhibit whereas rapamycin augments OPN-induced
ICAM-1 expression in MCF-7 cells. The data revealed
that OPN induces ICAM-1 expression through NF-κB
and AP-1 mediated pathway. Moreover, the results
showed that rapamycin augments OPN-induced ICAM-1
promoter activity in these cells. Furthermore, OPN
induces NF-κB activation and overexpression of mTOR
suppresses NF-κB activation in these cells. Earlier reports
have shown that inhibition of mTOR by rapamycin
induced NF-κB activity in response to thrombin in
endothelial cells [23].
Figure 7 OPN induces mTOR independent p70S6 kinase phosphorylation at Thr-421/Ser-424 through MEK/ERK pathway. A. MCF-7 cells 
were transiently transfected with wild type or rapamycin resistant mTOR. After 48 h, cells were either treated with OPN or pretreated with rapamycin 
and then treated with 0.5 μM OPN for 10 min. Cell lysates containing equal amount of total proteins were analyzed by western blot with anti-p-p70S6 
kinase (Thr-421/Ser-424) or anti-mTOR antibody. The blots were reprobed with anti-p70S6 kinase antibody. B. MCF-7 cells were pretreated with 0-500 
μM U0126 (MEK inhibitor) for 1 h and then treated with 0.5 μM OPN for 10 min. Cell lysates were analyzed by western blot with anti-p-p70S6 kinase 
(Thr-421/Ser-424) or anti-p-ERK1/2 antibody. The same blots were reprobed with anti-p70S6 kinase or anti-ERK2 antibody.Ahmed and Kundu Molecular Cancer 2010, 9:101
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Our data also revealed that overexpression of m T OR
suppresses OPN-induced AP-1 activation and rapamycin
enhances this OPN-induced effect. We also showed that
OPN regulates cross-talk between NF-κB and AP-1 that
leads to ICAM-1 expression in breast cancer cells. Here
we provide the experimental evidence that OPN induces
AP-1-DNA binding and overexpression of IκBα super
repressor suppresses OPN-induced AP-1 transactivation.
Moreover, the OPN-induced NF-κB activation is not
being controlled by AP-1. These data suggested that
OPN-induced cross talk between NF-κB and AP-1 is uni-
directional towards AP-1. Previous report indicated that
OPN regulates cell migration, adhesion, invasion, prolif-
eration and intracellular signaling by interacting with its
receptor αvβ3 integrin in various cell types ([10,33] and
[34]). Our data also showed that α vβ3 integrin blocking
antibody suppresses OPN-induced AP-1 transcriptional
activity in MCF-7 cells suggesting that OPN induces AP-
1 transcriptional activation by interacting with its recep-
tor αvβ3 intergrin. Thus, OPN upon binding with αvβ3
integrin induces AP-1 transcriptional activity through
NF-κB mediated pathway indicating a cross talk between
NF-κB and AP-1 which in turn regulates ICAM-1 expres-
sion. Recent reports indicated that several mTOR inhibi-
tors are currently under evaluation in preclinical and
clinical studies [35]. In this study, we have shown that
inhibition of mTOR and its downstream target p70S6
kinase by rapamycin potentiate OPN-induced ICAM-1
expression. The data are consistent with the earlier report
that inhibition of mTOR enhances thrombin-induced
ICAM-1 expression by accelerating and stabilizing NF-κB
activation in endothelial cells [23]. In our study, we have
evaluated the role of OPN and rapamycin on phosphory-
lations of mTOR and p70S6 kinase and the data suggested
that OPN does not phosphorylate mTOR at Ser-2448 and
p70S6 kinase at Thr-389 and Ser-371, but at Thr-421/Ser-
424 sites. However, rapamycin does not affect phospho-
rylation of mTOR at Ser-2448 and p70S6 kinase at Thr-
389 and Thr-421/Ser-424 but it does inhibit basal level of
phosphorylation of p70S6 kinase at Ser-371.
Phosphorylation of p70S6 kinase at Thr-421/Ser-424
exists in the autoinhibitory domain of carboxyl terminal,
Thr-229 in activation loop, Thr-389 and Ser-371 in the
linker domain, all of these are crucial for the activation of
p70S6 kinase [17,18]. Earlier reports suggest that phos-
phorylation of p70S6 kinase at Thr-421/Ser-424 alone is
Figure 8 Molecular mechanism of OPN-induced p70S6 kinase/mTOR regulated NF-κB/AP-1 mediated ICAM-1 expression in breast cancer 
cells. OPN induces αvβ3 integrin-mediated NF-κB/AP-1 dependent ICAM-1 expression. Overexpression of mTOR/p70S6 kinase suppresses OPN-in-
duced ICAM-1 expression in breast cancer cells.Ahmed and Kundu Molecular Cancer 2010, 9:101
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not sufficient for the activation of p70S6 kinase [36]. But
the phosphorylation of p70S6 kinase at Ser-371 is under
the control of mTOR and is directly responsible for p70S6
kinase activation ([17,36] and [37]). Our study revealed
that inhibition of mTOR activity by rapamycin suppresses
basal level phosphorylation of p70S6 kinase at Ser-371
which may possibly be the reason for increased OPN-
induced ICAM-1 expression and transactivation. More-
over, overexpression of mTOR and rapamycin have no
effect on p70S6 kinase phosphorylation at Thr-421/Ser-
424 which further confirmed that phosphorylation at this
site is not responsible for the activation of p70S6 kinase.
However, p70S6 kinase phosphorylation at Thr-421/Ser-
424 site is being suppressed by MEK/ERK inhibitor,
U0126. The data suggests that OPN-induced p70S6
kinase phosphorylation at Thr-421/Ser-424 site is not
being controlled by mTOR; rather it is being regulated
through MEK/ERK pathway. OPN has been reported as a
d i a g n o s t i c  m a r k e r  i n  p a t i e n t s  w i t h  b r e a s t  c a n c e r s  [ 3 1 ]
and suppression of tumor derived OPN by its antisense S-
oligonucleotide and siRNA has been shown to suppress
the in vitro proliferation, migration, and in vivo osteolytic
metastasis in nude rats [38-40]. Thus, a better under-
standing of the molecular mechanism of regulation of
ICAM-1 expression in response to OPN may help in
developing a novel therapeutic approach for the treat-
ment of breast cancer (Fig. 8).
Conclusion
This study highlights the potential role of OPN to induce
ICAM-1 expression through mTOR/p70S6 kinase path-
way in breast cancer cells. The findings emphasize the
importance of mTOR/p70S6 kinase pathway as a check
point to regulate ICAM-1 expression in response to OPN.
The data further revealed that OPN regulates cross talk
between transcription factors NF-κB and AP-1 which is
unidirectional towards AP-1 that in turn regulates
ICAM-1 expression. Moreover, the results deciphered the
role of OPN and rapamycin in regulating mTOR and
p70S6 kinase phosphorylations and involvement of MEK/
ERK pathway in this process. Breast cancer is one of the
most debilitating diseases and earlier reports have shown
that ICAM-1 plays important role in regulating invasion,
tumor growth and metastasis in breast cancer. Therefore
it is important to understand how OPN selectively regu-
late p70S6K/mTOR phosphorylation leading to NF-κB
dependent AP-1 mediated ICAM-1 expression in breast
cancer cells. Thus, the study suggests that blocking of
OPN-induced ICAM-1 expression through mTOR/p70S6
kinase signaling may be an important therapeutic target
for the management of breast cancer.
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